Примери за използване на Additional risk minimisation measures на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Additional risk minimisation measures.
The PRAC also reviewed responses from Member States in relation to the potential unmet medical need and proposals for additional risk minimisation measures.
The new additional risk minimisation measures.
The Committee considers that the benefit-risk balance of Zinbryta(daclizumab)remains favourable subject to the agreed amendments to the product information and the additional risk minimisation measures.
Additional risk minimisation measures(Humalog 200 units/ml).
The CMDh also considered that the effectiveness of these additional risk minimisation measures must be assessed through the conduct of a drug utilisation study.
Additional risk minimisation measures for Aranesp solution for injection in pre-filled pen.
This may be particularly important as the prescribers of IV formulations of valproate are expected to be different from the usual prescribers targeted during the implementation of additional risk minimisation measures.
They considered additional risk minimisation measures to be unnecessary.
In view of the above,the Committee considered that the benefit-risk balance of Tysabri remains favourable subject to the agreed amendments to the product information and additional risk minimisation measures.
Proposals for additional risk minimisation measures and pharmacovigilance activities.
The CMDh, through its representatives of Member States also considered feasibility at national level of some additional risk minimisation measures for which PRAC raised feasibility questions.
Despite additional risk minimisation measures having already been put in place, reports continued to be received.
As a consequence, the conditions or restrictions with regards to the safe andeffective use of the medicinal product should be updated to remove the additional risk minimisation measures.
Additional risk minimisation measures within a Risk management Plan were not considered necessary.
Given the accumulation of data since the implementation of the additional risk minimisation measures, the PRAC agreed with the MAH's proposal to remove the additional risk minimisation measures.
Additional risk minimisation measures include providing educational material to prescribers to ensure that only the appropriate patients are treated with the medicine.
The MAHs should update the risk management plan(RMP) for products with an existing RMP to include the additional risk minimisation measures and the additional pharmacovigilance activities agreed as part of this procedure.
The following additional risk minimisation measures are necessary for the safe and effective use of the product.
The CHMP concluded that the benefit-risk balance for adrenaline auto-injectors remains favourable subject to the agreed changes to the product information and the above-mentioned additional risk minimisation measures.
Furthermore, no additional risk minimisation measures were identified or proposed by the marketing authorisation holder to minimise the newly identified safety concerns.
The PRAC concluded that the benefit-risk of the hydroxyzine-containing products remains positive,provided that the agreed changes to the product information and the additional risk minimisation measures are implemented.
As additional risk minimisation measures, the PSUR submission cycle will be shortened to an annual submission and the monitoring of the effectiveness of the risk minimisation measures will be conducted through a drug utilisation study.
In view of all of the above,the PRAC concluded that the benefit-risk balance of Tysabri remains favourable subject to amendments to the product information and additional risk minimisation measures as described below.
Additional risk minimisation measures proposed by the marketing authorisation holder included a restriction of pack size to 2 weeks of treatment, the implementation of a treatment registry, and a long-term epidemiological cohort study.
The European Commission requested that the PRAC and the CMDh further consider any possible unmet medical need that could result from a suspension, as well as the feasibility andlikely effectiveness of additional risk minimisation measures.
Furthermore, the PRAC was requested to review any additional risk minimisation measures to ensure that these are optimal in terms of provision of information and delivery of effective risk management that is subject to appropriate monitoring.
The PRAC concluded that the benefit-risk balance for flupirtine containing medicinal products remains favourable in the treatment of acute pain subject to the agreed restrictions, contraindications, warnings,other changes to the product information and additional risk minimisation measures.
Therefore, the PRAC considered that additional risk minimisation measures could not mitigate the known risk of misuse by the intended target population and the associated potential serious harm caused by the injection of high molecular weight povidone(K90).
The PRAC, as a consequence, concluded that the benefit-risk balance of the hydroxyzinecontaining products identified in Annex I remains favourable, subject to the agreed amendments to the product information andadditional pharmacovigilance activities and additional risk minimisation measures.